Yearly zoledronic acid in postmenopausal osteoporosis.
de Nijs
Ron N J
RN
Westgeest
Antonius A A
AA
D001281:Atrial Fibrillation / Q000139:chemically induced*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002118:Calcium / Q000097:blood*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control*; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000097:blood; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D010281:Parathyroid Hormone; D000077211:Zoledronic Acid; D002118:Calcium